Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Organon & Co. Common Stock (NY:OGN)

9.920 UNCHANGED
Streaming Delayed Price Updated: 7:00 PM EDT, Oct 9, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Organon & Co. Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 297 companies achieved new lows for the year. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2022
Upgrades 
Via Benzinga
This Analyst Predicts $396 For Eli Lilly, Plus Raymond James Slashes PT On This Stock By Over 73%
Raymond James cut the price target for PolyPid Ltd. (NASDAQ: PYPD) from $15 to $4. PolyPid shares fell 7.7% to $1.32 in pre-market trading. 
Via Benzinga
Organon Expects Lower EBITDA Margin For FY22, Clocks Mixed Q2 Earnings
 
Via Benzinga
Amphastar's Generic Ganirelix Acetate Injection Scores FDA Approval
 
Via Benzinga
Merck Spinoff Organon Beats Quarterly Views, But Offers Dim Guidance
Organon's sales and earnings fell less than expected, but 2022 sales guidance missed. 
Via Investor's Business Daily
Stocks That Hit 52-Week Lows On Wednesday
  On Wednesday, 238 companies achieved new lows for the year. 
Via Benzinga
This Women Health Stock Gets Analyst Downgrade On 'Approvability Issues, Restructuring'
 
Via Benzinga
Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary
 
Via Benzinga
Samsung Bioepis and Organon Announce FDA Approval of Citrate-Free High-Concentration HUMIRA® Biosimilar HADLIMA™ (adalimumab-bwwd)
From Organon & Co.
Via Business Wire
A Look Into Healthcare Sector Value Stocks
  Understanding Value Stocks A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base... 
Via Benzinga
Organon: Q2 Earnings Insights
  Organon (NYSE:OGN) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings Organon reported in-line EPS of $1.25... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For August 5, 2022
Upgrades 
Via Benzinga
Organon Reports Results for the Second Quarter Ended June 30, 2022
From Organon & Co.
Via Business Wire
Organon and Cirqle Biomedical Enter Research Collaboration and License Agreement for Investigational Non-hormonal, On-demand Contraceptive Candidate
From Organon & Co.
Via Business Wire
Organon To Report Second Quarter Results and Host Conference Call on August 4, 2022
From Organon & Co.
Via Business Wire
Week In Review: Joincare Plans $300-$400 Million IPO On Swiss Exchange
Joincare Pharmaceutical of Shenzhen plans to list on the SIX Swiss stock exchange, an unusual venue for a China biopharma. The company said it aims to broaden its financing sources and increase global... 
Via Talk Markets
Organon Enters into Global License Agreement to Commercialize Henlius’ Investigational Perjeta® (Pertuzumab) and Prolia®/Xgeva® (Denosumab) Biosimilar Candidates
From Organon & Co.
Via Business Wire
On One Year Anniversary, Organon Introduces Global ESG Strategy and Commitments with Publication of Inaugural ESG Report
From Organon & Co.
Via Business Wire
Market Selloff
In a U.S. market selloff, the strong performance of mostly foreign issues was impressive. 
Via Talk Markets
Organon Easily Beats First-Quarter Expectations Despite Nexplanon Slip-Up
The firm's biggest product sustained a hit due to exchange rates and buying patterns. 
Via Investor's Business Daily
Organon Reports Results for the First Quarter Ended March 31, 2022
From Organon & Co.
Via Business Wire
Organon To Report First Quarter Results and Host Conference Call on May 5, 2022
From Organon & Co.
Via Business Wire
Organon Inks Licensing Pact For Daré Bioscience's Bacterial Vaginosis Treatment
Organon & Co (NYSE: OGN)  
Via Benzinga
Organon Enters into Global License Agreement to Commercialize Daré Bioscience’s XACIATO™ (clindamycin phosphate vaginal gel, 2%), FDA-Approved Treatment for Females 12 and Older with Bacterial Vaginosis (BV)
From Organon & Co.
Via Business Wire
Healthy Pharma Favorites
Here's a look at two drug makers that we recommend in our Growth & Income Portfolio. The stocks in this portfolio are generally higher-quality, larger-cap companies that have fallen out of favor. 
Via Talk Markets
AbbVie, Alvotech Resolve US Patent Dispute Related To Humira Biosimilar
Alvotech Holdings S.A. has entered into a settlement agreement with AbbVie Inc (NYSE: ABBV), allowing Alvotech to market AVT02 (100 mg/mL), its high-... 
Via Benzinga
Overview Of Value Stocks In The Healthcare Sector
What Defines a Value Stock? A value stock traditionally has a lower price when compared to stock prices of companies in the same industry. This indicates that the company may be... 
Via Benzinga
World Markets News For Thursday
Ericsson stock lost another 5.27% today in US markets. 
Via Talk Markets
Established Brands Hit Organon's Q4 Sales, Expects FY22 Sales Of Upto $6.4B
Organon & Co's (NYSE: OGN) Q4 FY21 sales decreased 1% to $1.6 billion, beating the consensus of $1.57 billion. Women's Health increased 6%, driven primarily... 
Via Benzinga
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.